Drugs that inhibit HIV-1 replication and prevent progression to AIDS do not1 eliminate HIV-1 proviruses from the chromosomes of long-lived CD4 + memory T 2 cells. To escape eradication by these antiviral drugs, or by the host immune 3 system, HIV-1 exploits poorly defined host factors that silence provirus 4 transcription. These same factors, though, must be overcome by all retroviruses, 5 including HIV-1 and other primate immunodeficiency viruses, in order to activate 6 provirus transcription and produce new virus. Here we show that Vpx and Vpr, 7 proteins from a wide range of primate immunodeficiency viruses, activate 8 provirus transcription in human CD4 + T cells. Provirus activation required the 9 DCAF1 adaptor that links Vpx and Vpr to the CUL4A/B ubiquitin ligase complex, 10 but did not require degradation of SAMHD1, a well-characterized target of Vpx 11 and Vpr. A loss-of-function screen for transcription silencing factors that mimic 12 the effect of Vpx on provirus silencing identified all components of the Human 13 Silencing Hub (HUSH) complex, FAM208A (TASOR/RAP140), MPHOSPH8 (MPP8), 14 PPHLN1 (PERIPHILIN), and MORC2. Vpx associated with the HUSH complex 15 components and decreased steady-state levels of these proteins in a DCAF-16 dependent manner. Finally, vpx and FAM208A knockdown accelerated HIV-1 and 17 SIV MAC replication kinetics in CD4 + T cells to a similar extent, and HIV-2 replication 18 required either vpx or FAM208A disruption. These results demonstrate that the 19 HUSH complex restricts transcription of primate immunodeficiency viruses and 20 thereby contributes to provirus latency. To counteract this restriction and 21 activate provirus expression, primate immunodeficiency viruses encode Vpx and 22 Vpr proteins that degrade HUSH complex components. 23 2017), whose demonstration that cells may carry Rous sarcoma virus genetic 479 information in the absence of any infectious virus production provided support to the 480 proviral hypothesis. We thank Lisa Cavacini for anti-CD3 and anti-CD28 antibodies, and 481 Akio Adachi and Mikako Fujita for pGL-St and pGL-An. The following reagents were 482 obtained through the AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Tat-483